

Press Release

ProStrakan Group plc (the "Company")

Total Voting Rights

For the purposes of the Transparency Directive, the Company's total issued share capital at the date of this notice is 201,294,872.

The Company's issued and fully paid share capital consists of 201,294,872 ordinary shares of 5 pence each, which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FSA's Disclosure and Transparency Rules.

The company holds no shares in Treasury.

Ends

31 March 2010

Further enquiries:

Callum Spreng 01896 664000
Corporate Communications
ProStrakan

Jon Coles/Justine McIlroy 020 7404 5959
Brunswick Group

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels, UK, and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

www.prostrakan.com